このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Barinthus Biotherapeutics 将来の成長

Future 基準チェック /06

Barinthus Biotherapeuticsの収益は年間1.7%で減少すると予測されていますが、年間収益は年間2%で増加すると予測されています。EPS は年間減少すると予測されています。自己資本利益率は 3 年後に-162.7% 1.7%なると予測されています。

主要情報

-1.7%

収益成長率

-1.7%

EPS成長率

Biotechs 収益成長	24.1%
収益成長率	2.0%
将来の株主資本利益率	-162.7%
アナリストカバレッジ	Low
最終更新日	13 Jun 2024

今後の成長に関する最新情報

Recent updates

Here's Why We're Watching Barinthus Biotherapeutics' (NASDAQ:BRNS) Cash Burn Situation

Apr 05

Analysts Just Made An Incredible Upgrade To Their Vaccitech plc (NASDAQ:VACC) Forecasts

Aug 15

Vaccitech plc Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Aug 13

Vaccitech GAAP EPS of $0.41, revenue of $17.06M

Aug 09

Growth Investors: Industry Analysts Just Upgraded Their Vaccitech plc (NASDAQ:VACC) Revenue Forecasts By 51%

May 19

Vaccitech: Aiming For A Cure In Chronic Hepatitis B

Apr 03

Vaccitech: The Next Big Vaccine Trade

Jun 27

Vaccitech EPS misses by $0.69, beats on revenue

Jun 14

業績と収益の成長予測

NasdaqGM:BRNS - アナリストの将来予測と過去の財務データ ( )USD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2026	1	-102	N/A	N/A	3
12/31/2025	N/A	-77	N/A	N/A	3
12/31/2024	N/A	-67	N/A	N/A	3
3/31/2024	0	-71	-63	-60	N/A
12/31/2023	1	-73	-56	-51	N/A
9/30/2023	7	-77	-49	-43	N/A
6/30/2023	13	-55	-28	-20	N/A
3/31/2023	30	-15	-19	-11	N/A
12/31/2022	45	5	-21	-14	N/A
9/30/2022	38	11	-17	-11	N/A
6/30/2022	32	-1	-29	-25	N/A
3/31/2022	15	-33	-33	-31	N/A
12/31/2021	0	-51	-34	-33	N/A
9/30/2021	1	-46	-30	-30	N/A
6/30/2021	4	-41	-29	-28	N/A
3/31/2021	4	-29	-15	-15	N/A
12/31/2020	5	-18	-11	-11	N/A
12/31/2019	7	-21	-19	-19	N/A

アナリストによる今後の成長予測

収入対貯蓄率: BRNS今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: BRNS今後 3 年間、利益が出ない状態が続くと予測されています。

高成長収益: BRNS今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: BRNS来年は収益がないと予測されています。

高い収益成長: BRNS来年は収益がないと予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: BRNS 3 年以内に赤字になると予測されています。

Barinthus Biotherapeutics 将来の成長

Future 基準チェック /06

主要情報

今後の成長に関する最新情報

Consensus revenue estimates increase by 29%

Consensus revenue estimates decrease by 20%, EPS upgraded

Price target decreased by 24% to US$9.31

Consensus revenue estimates increase by 26%

Consensus revenue estimates decrease by 53%, EPS upgraded

Consensus revenue estimates decrease by 28%

Recent updates

Barinthus Biotherapeutics plc Plans to Priority on the Development of VTP-300 in Chronic Hepatitis B Virus Infection, or CHB, and VTP-1000 in Celiac Disease

Barthus Biotherapeutics plc Announces Updated Data from Two Clinical Trials in People with Chronic Hepat B

First quarter 2024 earnings released: US$0.40 loss per share (vs US$0.48 loss in 1Q 2023)

Barinthus Biotherapeutics plc Appoints Leon Hooftman as Chief Medical Officer, Effective from Beginning of June 2024

BarinthuBarinthus Biotherapeutics plc Announces Topline Data from Phase 1b/2 APOLLO Trial of VTP-200 in Persistent High-Risk Human Papillomavirus (HPV) Infections

Here's Why We're Watching Barinthus Biotherapeutics' (NASDAQ:BRNS) Cash Burn Situation

New minor risk - Share price stability

Consensus revenue estimates increase by 29%

Barinthus Biotherapeutics plc, Annual General Meeting, May 10, 2024

New major risk - Revenue size

Full year 2023 earnings released: US$1.91 loss per share (vs US$0.14 profit in FY 2022)

Insufficient new directors

New minor risk - Market cap size

Consensus revenue estimates decrease by 20%, EPS upgraded

Arbutus Biopharma Corporation and Barinthus Biotherapeutics plc Present Preliminary Data from Phase 2A Clinical Trial Combining Imdusiran with VTP-300 at AASLD

Third quarter 2023 earnings released: US$0.36 loss per share (vs US$0.22 profit in 3Q 2022)

Vaccitech plc(NasdaqGM:VACC) dropped from NASDAQ Composite Index

Price target decreased by 24% to US$9.31

Consensus revenue estimates increase by 26%

Consensus revenue estimates decrease by 53%, EPS upgraded

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Vaccitech plc Announces Retirement of Margaret Marshall as Chief Medical Officer

We Think Vaccitech (NASDAQ:VACC) Can Afford To Drive Business Growth

Vaccitech plc Announces Positive Final Data EASL Congress for Phase 1B/2 HBV002 Study in Adults with Chronic Hepatitis B

Vaccitech plc Doses First Patient in Pca001, A Prostate Cancer Phase 1/2 Clinical Trial of Vtp-850

Consensus revenue estimates decrease by 28%

First quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Consensus revenue estimates increase by 12%, EPS downgraded

Price target decreased by 28% to US$14.33

Investor sentiment improves as stock rises 23%

Investor sentiment deteriorates as stock falls 17%

Vaccitech Appoints Nadège Pelletier as Chief Scientific Officer

Vaccitech's (NASDAQ:VACC) Earnings Are Of Questionable Quality

Consensus forecasts updated

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Consensus forecasts updated

Vaccitech plc Provides Update on Ongoing VTP-300 Phase 1b/2a Trial Showing Sustained Reductions of HBsAg in Patients with Chronic Hepatitis B

Vaccitech plc Doses First Patients in HBV003, a Phase 2b Clinical Trial of VTP-300 Immunotherapeutic Candidate for Chronic HBV Patients

Vaccitech plc Announces Publication of Research in Preclinical Animal Models Demonstrating the Potential of Vaccitech’s SNAPvax

Vaccitech plc Promotes Gemma Brown as Chief Financial Officer

Vaccitech promotes Gemma Brown to CFO

Consensus revenue estimates increase by 61%

Analysts Just Made An Incredible Upgrade To Their Vaccitech plc (NASDAQ:VACC) Forecasts

Vaccitech plc Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Price target decreased to US$19.50

Vaccitech GAAP EPS of $0.41, revenue of $17.06M

Vaccitech plc Announces an Update to the Interim Analysis of Safety and Efficacy Data from the HBV002 Study

Arbutus Biopharma Corporation and Vaccitech plc Dose First Patient in Phase 2a Clinical Trial Combining Therapies for the Treatment of Chronic Hepatitis B Virus

Growth Investors: Industry Analysts Just Upgraded Their Vaccitech plc (NASDAQ:VACC) Revenue Forecasts By 51%

Consensus revenue estimates increase by 51%

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Vaccitech plc, Annual General Meeting, Jun 15, 2022

Less than half of directors are independent

Consensus forecasts updated

Vaccitech: Aiming For A Cure In Chronic Hepatitis B

Less than half of directors are independent

Consensus forecasts updated

Consensus forecasts updated

Vaccitech plc Announces First Patient Dose in Phase I/Iia Trial of Lung Cancer Immunotherapy Vaccine

Vaccitech plc (NasdaqGM:VACC) acquired Avidea Technologies for $40 million.

Third quarter 2021 earnings released: US$0.13 loss per share

Vaccitech: The Next Big Vaccine Trade

Vaccitech EPS misses by $0.69, beats on revenue

Vaccitech plc has completed an IPO in the amount of $110.5 million.

業績と収益の成長予測

アナリストによる今後の成長予測

一株当たり利益成長率予想